Erratum to 'The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting' [J. Clin. Virol. 41 (4) 2008 243-254] (DOI:10.1016/j.jcv.2007.11.017);The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting

Journal of Clinical Virology

Volumn 41, Issue 4, 2008, Pages 243-254

  Barclay, Stephen ^a   Pol, Stanislas ^b   Mutimer, David ^c   Benhamou, Yves ^d   Mills, Peter R ^a   Hayes, Peter C ^e   Cameron, Sheila ^a   Cameron, William ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b Hôpital Cochin ^*  (France)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Chemotherapy; Hepatitis B; HIV; Immunocompromised host; Kidney transplantation; Liver transplantation

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; CORTICOSTEROID; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; METHOTREXATE; RITUXIMAB; STEROID; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG WITHDRAWAL; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOPROPHYLAXIS; KIDNEY GRAFT; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MIXED INFECTION; MONOTHERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 40849135610     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2008.03.021     Document Type: Erratum

References (82)

1. Angelico M., Di Paolo D., Trinito M.O., Petrolati A., Araco A., Zazza S., et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35 (2002) 176-181
2. Angus P.W., McCaughan G.W., Gane E.J., Crawford D.H., and Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 6 (2000) 429-433
3. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 44 (2006) S90-S94
4. Benhamou Y., Fleury H., Trimoulet P., Pellegrin I., Urbinelli R., Katlama C., et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 (2006) 548-555
5. Benhamou Y., Thibault V., Vig P., Calvez V., Marcelin A.G., Fievet M.H., et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 44 (2006) 62-67
6. Brook M.G., Gilson R., and Wilkins E. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005). HIV Med 6 Suppl. 2 (2005) 84-95
7. Burdick R.A., Bragg-Gresham J.L., Woods J.D., Hedderwick S.A., Kurokawa K., Combe C., et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 63 (2003) 2222-2229
8. Buti M., Mas A., Prieto M., Casafont F., Gonzalez A., Miras M., et al. The five year follow-up of a randomized study comparing lamivudine with lamivudine + HB investigating the prevention of HBV recurrence after liver transplantation. J Hepatol 44 2 (2006) s57-s157
9. Calabrese L.H., Zein N.N., and Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65 (2006) 983-989
10. Chan T.M., Fang G.X., Tang C.S., Cheng I.K., Lai K.N., and Ho S.K. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36 (2002) 1246-1252
11. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
12. Cheng A.L. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 87 (1996) 1202
13. Colin J.F., Cazals-Hatem D., Loriot M.A., Martinot-Peignoux M., Pham B.N., Auperin A., et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29 (1999) 1306-1310
14. Colono R., Rose R., Baldick C., Pokornowski K., Eggers B., Plym M., et al. Week-48 resistance surveillance of HIVHBV coinfected patients treated with entecavir in study AI463038. Program and abstracts of the 13th conference on retroviruses and opportunistic infections. Denver, Colorado, USA, 2006 (2006)
15. Dan Y.Y., Wai C.T., Yeoh K.G., and Lim S.G. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 12 (2006) 736-746
16. Delaugerre C., Marcelin A.G., Thibault V., Peytavin G., Bombled T., Bochet M.V., et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 46 (2002) 1586-1588
17. Di P.D., Lenci I., Trinito M.O., Carbone M., Longhi C., Tisone G., et al. Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins. Dig Liver Dis 38 (2006) 749-754
18. Durlik M., Gaciong Z., Rancewicz Z., Rowinska D., Wyzgal J., Kozlowska B., et al. Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha. Transplant Proc 27 (1995) 958-959
19. Esteve M., Saro C., Gonzalez-Huix F., Suarez F., Forne M., and Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53 (2004) 1363-1365
20. Fabrizi F., Lunghi G., and Martin P. Hepatitis B virus infection in hemodialysis: recent discoveries. J Nephrol 15 (2002) 463-468
21. Fabrizi F., Martin P., Dixit V., Kanwal F., and Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 5 (2005) 2913-2921
22. Filik L., Karakayali H., Moray G., Dalgic A., Emiroglu R., Ozdemir N., et al. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen. Transplant Proc 38 (2006) 496-498
23. Finelli L., Miller J.T., Tokars J.I., Alter M.J., and Arduino M.J. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18 (2005) 52-61
24. Fontaine H., Vallet-Pichard A., Chaix M.L., Currie G., et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 80 (27-10-2005) 1086-1092
25. Galbraith R.M., Eddleston A.L., Williams R., and Zuckerman A.J. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2 (1975) 528-530
26. Gane E.J., Angus P.W., Strasser S., Crawford D.H., Ring J., Jeffrey G.P., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132 (2007) 931-937
27. Gish R.G., Trinh H., Leung N., Chan F.K., Fried M.W., Wright T.L., et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 43 (2005) 60-66
28. Goyal S., Pai S.K., Kelkar R., and Advani S.H. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res 22 (1998) 193-195
29. Grob P., Jilg W., Bornhak H., Gerken G., Gerlich W., Gunther S., et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 62 (2000) 450-455
30. Han S.H., Ofman J., Holt C., King K., Kunder G., Chen P., et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 6 (2000) 741-748
31. Harnett J.D., Parfrey P.S., Kennedy M., Zeldis J.B., Steinman T.I., and Guttmann R.D. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 11 (1988) 210-213
32. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 (2006) 59-68
33. Hung K.Y., Lee K.C., Yen C.J., Wu K.D., Tsai T.J., and Chen W.Y. Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. Nephrol Dial Transplant 12 (1997) 180-183
34. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
35. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
36. Karasu Z., Ozacar T., Akarca U., Ersoz G., Erensoy S., Gunsar F., et al. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 12 (2005) 212-215
37. Kim J.H., Bang Y.J., Park B.J., Yoo T., Kim C.W., Kim T.Y., et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res 93 (2002) 471-477
38. Kim W.R., Poterucha J.J., Kremers W.K., Ishitani M.B., and Dickson E.R. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 10 (2004) 968-974
39. Kohrt H.E., Ouyang D.L., and Keeffe E.B. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24 (2006) 1003-1016
40. Konopnicki D., Mocroft A., de Wit S., Antunes F., Ledergerber B., Katlama C., et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19 (2005) 593-601
41. Lalazar G., Rund D., and Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136 (2007) 699-712
42. Lau G.K., Leung Y.H., Fong D.Y., Au W.Y., Kwong Y.L., Lie A., et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99 (2002) 2324-2330
43. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 (2003) 1742-1749
44. Law J.K., Ho J.K., Hoskins P.J., Erb S.R., Steinbrecher U.P., and Yoshida E.M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46 (2005) 1085-1089
45. Lim S.G., Ng T.M., Kung N., Krastev Z., Volfova M., Husa P., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 166 (2006) 49-56
46. Lo C.M., Lau G.K., Chan S.C., Fan S.T., and Wong J. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 7 (2007) 434-439
47. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
48. Lok A.S., Liang R.H., Chiu E.K., Wong K.L., Chan T.K., and Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100 (1991) 182-188
49. Marcucci F., Mele A., Spada E., Candido A., Bianco E., Pulsoni A., et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 91 (2006) 554-557
50. Markovic S., Drozina G., Vovk M., and Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46 (1999) 2925-2930
51. Markowitz J.S., Martin P., Conrad A.J., Markmann J.F., Seu P., Yersiz H., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28 (1998) 585-589
52. Marzano A., Salizzoni M., Bernardi-Venon W., Smedile A., Franchello A., Ciancio A., et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34 (2001) 903-910
53. McCaughan G.W., Spencer J., Koorey D., Bowden S., Bartholomeusz A., Littlejohn M., et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 5 (1999) 512-519
54. McGory R.W., Ishitani M.B., Oliveira W.M., Stevenson W.C., McCullough C.S., Dickson R.C., et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 61 (1996) 1358-1364
55. McMahon M.A., Jilek B.L., Brennan T.P., Shen L., Zhou Y., Wind-Rotolo M., et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 356 (2007) 2614-2621
56. Mindikoglu A.L., Regev A., and Schiff E.R. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 4 (2006) 1076-1081
57. Myers R.P., Tainturier M.H., Ratziu V., Piton A., Thibault V., Imbert-Bismut F., et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 39 (2003) 222-230
58. Nakamura Y., Motokura T., Fujita A., Yamashita T., and Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 78 (1996) 2210-2215
59. Perrillo R.P., Wright T., Rakela J., Levy G., Schiff E., Gish R., et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
60. Pioltelli P., Gargantini L., Cassi E., Santoleri L., Bellati G., Magliano E.M., et al. Hepatitis C virus in non-Hodgkin's lymphoma. A reappraisal after a prospective case-control study of 300 patients. Lombart Study Group of HCV-Lymphoma. Am J Hematol 64 (2000) 95-100
61. Puoti M., Torti C., Bruno R., Filice G., and Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44 (2006) S65-S70
62. Roche B., Feray C., Gigou M., Roque-Afonso A.M., Arulnaden J.L., Delvart V., et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 38 (2003) 86-95
63. Rodrigues A., Morgado T., Areias J., Silvestre F., Pinho L., Alves H., et al. Limited benefits of INF-alpha therapy in renal graft candidates with chronic viral hepatitis B or C. Transplant Proc 29 (1997) 777-780
64. Rosenau J., Bahr M.J., Tillmann H.L., Trautwein C., Klempnauer J., Manns M.P., et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34 (2001) 895-902
65. Rosenau J., Hooman N., Rifai K., Solga T., Tillmann H.L., Grzegowski E., et al. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int 19 (2006) 828-833
66. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
67. Sanchez-Fueyo A., Rimola A., Grande L., Costa J., Mas A., Navasa M., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31 (2000) 496-501
68. Schiff E., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13 (2007) 349-360
69. Soriano V., Puoti M., Bonacini M., Brook G., Cargnel A., Rockstroh J., et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 19 (2005) 221-240
70. Starkel P., Stoffel M., Lerut J., and Horsmans Y. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 11 (2005) 1228-1234
71. Talamini R., Montella M., Crovatto M., Dal Maso L., Crispo A., Negri E., et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 110 (2004) 380-385
72. Terrault N.A., Zhou S., Combs C., Hahn J.A., Lake J.R., Roberts J.P., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24 (1996) 1327-1333
73. Thio C.L., Seaberg E.C., Skolasky Jr. R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360 (14-12-2002) 1921-1926
74. Todo S., Demetris A.J., Van Thiel D., Teperman L., Fung J.J., and Starzl T.E. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13 (1991) 619-626
75. Varaut A., Fontaine H., Serpaggi J., Verkarre V., Vallet-Pichard A., Nalpas B., et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 80 (2005) 1550-1555
76. Weitberg A.B., Weitzman S.A., Watkins E., Hinkle C., O'Rourke S., and Dienstag J.L. Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy. J Clin Oncol 3 (1985) 718-722
77. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., and Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119 (1993) 312-323
78. Yao F.Y., Osorio R.W., Roberts J.P., Poordad F.F., Briceno M.N., Garcia-Kennedy R., et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 5 (1999) 491-496
79. Yeo W., Hui E.P., Chan A.T., Ho W.M., Lam K.C., Chan P.K., et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 28 (2005) 379-384
80. Yeo W., Zee B., Zhong S., Chan P.K., Wong W.L., Ho W.M., et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90 (2004) 1306-1311
81. Yoshida E.M., Erb S.R., Partovi N., Scudamore C.H., Chung S.W., Frighetto L., et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 5 (1999) 520-525
82. Zheng S., Chen Y., Liang T., Lu A., Wang W., Shen Y., et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 12 (2006) 253-258